These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37242487)

  • 1. Diosgenin and Monohydroxy Spirostanol from
    Shalayel MHF; Al-Mazaideh GM; Alanezi AA; Almuqati AF; Alotaibi M
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
    Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
    Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
    Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
    Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2.
    Martiniano B
    J Mol Model; 2021 Mar; 27(4):105. PubMed ID: 33686576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic inhibition of gastric cancer-associated bacteria
    Akash S; Bayıl I; Mahmood S; Mukerjee N; Mili TA; Dhama K; Rahman MA; Maitra S; Mohany M; Al-Rejaie SS; Ali N; Semwal P; Sharma R
    Heliyon; 2023 Oct; 9(10):e20670. PubMed ID: 37876433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unveiling promising phytocompounds from Moringa oleifera as dual inhibitors of EGFR
    Masudur Rahman Munna M; Touki Tahamid Tusar M; Sajnin Shanta S; Hossain Ahmed M; Sarafat Ali M
    J Genet Eng Biotechnol; 2024 Sep; 22(3):100406. PubMed ID: 39179328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.
    Nakayama A; Takagi S; Yusa T; Yaguchi M; Hayashi A; Tamura T; Kawakita Y; Ishikawa T; Ohta Y
    J Cancer; 2013; 4(7):557-65. PubMed ID: 23983820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational investigation of
    Yousaf MA; Anwer SA; Basheera S; Sivanandan S
    J Biomol Struct Dyn; 2024; 42(4):1901-1923. PubMed ID: 37154824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of phytocompounds as potent inhibitors of sodium/glucose cotransporter-2 leading to diabetes treatment.
    Swargiary A; Daimari M; Swargiary A; Biswas A; Brahma D; Singha H
    J Biomol Struct Dyn; 2024 Feb; ():1-14. PubMed ID: 38379332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach.
    Lamichhane S; Rai RP; Khatri A; Adhikari R; Shrestha BG; Shrestha SK
    J Biomol Struct Dyn; 2023 Feb; 41(3):897-911. PubMed ID: 34957911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2.
    Balbuena-Rebolledo I; Padilla-Martínez II; Rosales-Hernández MC; Bello M
    Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives.
    Elkamhawy A; Son S; Lee HY; El-Maghrabey MH; Hamd MAE; Alshammari SO; Abdelhameed AA; Alshammari QA; Abdeen A; Ibrahim SF; Mahdi WA; Alshehri S; Alnajjar R; Choi WJ; Al-Karmalawy AA; Lee K
    Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Rolta R; Yadav R; Salaria D; Trivedi S; Imran M; Sourirajan A; Baumler DJ; Dev K
    J Biomol Struct Dyn; 2021 Nov; 39(18):7017-7034. PubMed ID: 32851912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG
    Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2.
    Bello M; Guadarrama-García C; Rodriguez-Fonseca RA
    J Comput Aided Mol Des; 2020 Mar; 34(3):293-303. PubMed ID: 31828486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reckoning apigenin and kaempferol as a potential multi-targeted inhibitor of EGFR/HER2-MEK pathway of metastatic colorectal cancer identified using rigorous computational workflow.
    Sharma A; Sinha S; Rathaur P; Vora J; Jha PC; Johar K; Rawal RM; Shrivastava N
    Mol Divers; 2022 Dec; 26(6):3337-3356. PubMed ID: 35147860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.